Pharmaceutical News

RSS

Women with polycystic ovary syndrome lose more weight when they take two drugs

Women with polycystic ovary syndrome, or PCOS, lost significantly more weight when they took two drugs that are traditionally used to treat diabetes, rather than either drug alone, a study from Slovenia demonstrates. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Study: Vitamin D supplementation may help delay early onset of puberty in girls

Vitamin D supplementation may help delay early onset of puberty in girls, a new clinical study finds. The results were presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Santarus, Inc. and Pharming Group NV today announced that the U.S. Food and Drug Administration has accepted for filing the Biologics License Application for the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 IU/kg.

18 Jun 2013

University of Michigan poll: 61% of adults don't know when they last vaccinated against pertussis

Cases of pertussis, also known as whooping cough, are on the rise in the U.S., recently reaching their highest level in 50 years. The disease can be serious or even fatal to newborns who have not yet received vaccinations.

18 Jun 2013

Drug increases amount of energy burned by fat tissue and promotes weight loss

A drug that mimics the activity of thyroid hormone significantly increases the amount of energy burned by fat tissue and promotes weight loss, an animal study of metabolism finds. The results were presented Sunday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Vaccine given to newborns 60% effective against rotavirus in Ghana

Mayo Clinic and other researchers have shown that a vaccine given to newborns is at least 60 percent effective against rotavirus in Ghana. Rotavirus causes fever, vomiting and diarrhea, which in infants can cause severe dehydration.

18 Jun 2013

Pyrvinium pamoate inhibits drug-resistant prostate cancer

A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

TSRI scientists identify highly promising new anti-tuberculosis compound

An international team led by scientists at The Scripps Research Institute, the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis bacterium in two different ways.

18 Jun 2013

Academies recommend ways to prevent antibiotic resistance, to develop antibiotics more quickly

Joint press release by the Academy of Sciences and Humanities in Hamburg and the German National Academy of Sciences Leopoldina

17 Jun 2013

Bazedoxifene used for treating osteoporosis stops growth of breast cancer cells

A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.

17 Jun 2013

U.S. MMJ market to quadruple in size over the next five years, predict analysts

Neutra Corp., a provider of all-natural wellness solutions, welcoms a new law passed in Nevada last week allowing medical marijuana patients to obtain their medicine from dispensaries at last.

17 Jun 2013

Transition, Lilly amend agreement to address future development of TT-401

Transition Therapeutics Inc. announced that Eli Lilly and Company has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401.

17 Jun 2013

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Genmab A/S and ADC Therapeutics Sarl, announced today an agreement to develop a new antibody-drug conjugate product combining Genmab's HuMax-TAC antibody and ADC Therapeutics' PBD-based warhead and linker technology.

17 Jun 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

Mayo Clinic researchers say that adolescents with chronic pain need to avoid medical marijuana

Adolescents can have chronic pain, just like adults. It can interfere with normal development, making it difficult for teens to attend school, socialize or be physically active, the cause may be hard to find, and medications are sometimes tried without success. As patients, their parents and physicians search for solutions, there is one increasingly available option they should avoid, Mayo Clinic researchers say: medical marijuana.

17 Jun 2013

Eli Lilly, BIPI support ADA's call for independent review of incretin-based therapies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company support the American Diabetes Association call for an independent review of the safety data of incretin-based therapies.

17 Jun 2013

Bristol-Myers Squibb, AstraZeneca release statement on ADA's efforts toward incretin-based therapies

Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.

17 Jun 2013

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.

17 Jun 2013

Study surveys physicians regarding prescribing of brand drugs over generics

In the fight to win new patients, the importance of prescription sampling programs has never been greater.

15 Jun 2013

Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

Emory University today announced an innovative new public-private drug development enterprise that will transition scientific discoveries more rapidly and efficiently from university laboratories into the marketplace. The new venture is expected to provide global solutions to address worldwide drug development and commercialization needs.

15 Jun 2013